Significant Weight Loss with Endoscopic Sleeve Gastroplasty Over Semaglutide in Recent Study

Recent Study Highlights

A groundbreaking study presented at ESGE Days 2026 in Milan has uncovered significant findings concerning weight loss methods for individuals facing obesity. The research compares the effectiveness of endoscopic sleeve gastroplasty (ESG) and oral semaglutide, a commonly prescribed medication for weight management.

Overview of the Study

This retrospective cohort study involved 150 patients who were treated in standard clinical environments. Researchers evaluated the health outcomes of these patients over a six-month period following the procedures. The results indicate a remarkable difference in weight loss between the two approaches. Patients who underwent ESG experienced an average total body weight loss of 12.7%, whereas those on oral semaglutide (14 mg dosage) managed to lose only 8.7%. This translates to a statistically significant difference of roughly 4% (p=0.0001) in weight loss. Even after adjusting for factors like age, sex, and initial body mass index, the ESG results remained robust.

Weight Loss Outcomes

The implications of these results are profound, especially for individuals seeking options to combat obesity. The study revealed that 70% of the ESG group achieved at least 10% total body weight loss at the six-month mark, compared to just 43% in the semaglutide group. Furthermore, 36% of the ESG patients achieved a loss of 15% or more, while only 7% of the semaglutide group reached that milestone.

Notably, the safety profile for both treatments showed comparable adverse event rates, which were predominantly mild gastrointestinal symptoms. Importantly, no serious complications or deaths were reported among participants in either group.

Expert Insights

Dr. Nitin G. Jagtap, the lead author of the study, addressed the clinical relevance of these findings. He noted, "In real-world practice, patients frequently weigh the options of a procedural intervention versus medication, and until now, there has been limited data available to inform that choice. Our focus on oral semaglutide reflects the prevalent treatment option during our study period, contributing to realistic and applicable clinical information."

Dr. Jagtap further emphasized the significance of a 4% difference in weight loss, asserting that it may lead to better management of related health conditions such as diabetes and fatty liver disease. He stressed the importance of personalized treatment decisions, and how ESG, being a one-off procedure, stands in contrast to the ongoing commitment required for daily medication like semaglutide.

The Path Forward

Concluding, Dr. Jagtap remarked that the future of obesity treatment lies in tailoring approaches to fit individual patient needs, cultivating a blend of procedural and pharmacological methods. As treatment options continue evolving, the emphasis on patient preferences and adherence will be pivotal in defining successful outcomes in managing obesity effectively.

This study sheds light on the critical question of weight loss management options in contemporary clinical practice, offering a tangible viewpoint for both patients and healthcare providers navigating the complexities of obesity treatment.